IP Library Granted Patent US 12,433,944
Granted Patent B2
US 12,433,944 · App. 17/052,707 · Granted Oct 7, 2025

Vaccine composition

Inventors: Sumi Biswas (Oxford, GB); Jing Jin (Oxford, GB); Rebecca Alice Dabbs (Oxford, GB); Genevieve Marie Catherine Labbé (Oxford, GB)
Assignee: SpyBiotech Limited
A61K39/245A61K39/12A61P31/14A61P31/22A61K2039/5258A61K2039/545C12N2710/16123C12N2710/16134C12N2760/18523C12N2760/18534
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,433,944
App. No.
17/052,707
Granted
Oct 7, 2025
Kind
B2
Abstract

The present invention relates to vaccine compositions, most notably vaccine compositions wherein the antigenic component is large, for example over 50 kDa, or multimeric, i.e. comprised of subunits. Such antigenic components are of particular interest, because they may represent antigenic components from pathogens that currently it is not possible to vaccinate against. The invention relates to a composition comprising a particle displaying an antigenic component, wherein said composition comprises an antigenic component comprising a first peptide tag, and a moiety comprising a second peptide tag, wherein the antigenic component and the moiety are linked via an isopeptide bond between said first and second peptide tags, and wherein the antigenic component is over 50 kDa, or alternatively is multimeric.

Claims (21)

1. A composition comprising a virus-like particle displaying an antigenic component, wherein said composition comprises:

i) an antigenic component comprising a first peptide tag, and

ii) a moiety comprising a second peptide tag,

wherein the antigenic component and the moiety are linked via an isopeptide bond between said first and second peptide tags, wherein the antigenic component is over 50 kDa and is a multimer;

wherein the moiety is a surface antigen of the hepatitis B virus (HBsAg) and multimerises to form the virus-like particle;

wherein the first peptide tag is a SpyTag having the amino acid sequence set out in SEQ ID NO: 30; and

wherein the second peptide tag is a SpyCatcher having the amino acid sequence set out in SEQ ID NO: 38.

2. The composition of claim 1 , wherein the antigenic component is an immunogenic component of an HCMV pentamer comprising one or more of gH, gL, pUL128, pUL130, or pUL131 subunits.

3. The composition of claim 2 , wherein the first peptide tag is attached to the gH subunit.

4. The composition of claim 1 , wherein the antigenic component comprises an immunogenic component of an RSV-F protein.

5. The composition of claim 4 , wherein the immunogenic component of the RSV-F protein is a pre-fusion F protein.

6. The composition of claim 5 , wherein the immunogenic component of the RSV pre-fusion F protein comprises a trimer of F 1 and F 2 subunits.

7. The composition of claim 4 , wherein the RSV-F protein has the amino acid sequence set out in any one of SEQ ID Nos: 50, 51, 52, 56, 57, or 58.

8. The composition of claim 5 , wherein the first peptide tag is attached to a C-terminus of the pre-fusion F protein.

9. The composition of claim 1 , wherein the antigenic component is attached to the SpyTag via a linker.

10. The composition of claim 1 , wherein the moiety is attached to the SpyCatcher through a linker.

11. The composition of claim 1 , wherein the composition is an immunogenic or vaccine composition.

12. A kit comprising a composition comprising a first immunogenic composition and one or more booster composition(s) comprising a second immunogenic composition wherein said first and/or second immunogenic compositions comprise a composition as claimed in claim 1 .

13. The composition of claim 2 , wherein the immunogenic component of the HCMV pentamer comprises the gH, gL, PUL128, pUL130, and pUL131 subunits.

14. The composition of claim 13 , wherein the gH subunit comprises a truncated transmembrane domain having an amino acid sequence as set out in SEQ ID NO: 28 or SEQ ID NO: 60.

15. A pharmaceutical composition comprising the composition of claim 1 and a pharmaceutically acceptable buffer, excipient, carrier, adjuvant, or combination thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 8, 2021
From: JIN, JING; DABBS, REBECCA ALICE; LABBÉ, GENEVIEVE MARIE CATHERINE; BISWAS, SUMI
To: SPYBIOTECH LIMITED
Reel/Frame 055860/0833 →
Priority Claims (2)
GB 1807376 · May 4, 2018 · national
GB 1807378 · May 4, 2018 · national
Continuity (1)
Related Publication 20210128717A1 · May 6, 2021
References Cited (64)
US 5767250A · Spaete · 1998 [cited by applicant]
US 9399059B2 · Morrison · 2016 [cited by examiner]
US 9683022B2 · Carfi · 2017 [cited by applicant]
US 10287322B2 · Carfi · 2019 [cited by applicant]
CN 106456724A · 2017 [cited by applicant]
CN 107875382A · 2018 [cited by applicant]
EP 2222710 · 2016 [cited by applicant]
GB 17057506 · 2017 [cited by applicant]
GB 17064304 · 2017 [cited by applicant]
WO WO2011098772A1 · 2011 [cited by applicant]
WO 2012034025A2 · 2012 [cited by applicant]
WO WO2014005959A1 · 2014 [cited by applicant]
WO WO2014160463A1 · 2014 [cited by applicant]
WO WO2016067239A1 · 2016 [cited by applicant]
WO WO2016112921A1 · 2016 [cited by examiner]
WO WO2016193746A1 · 2016 [cited by applicant]
WO WO2017172890A1 · 2017 [cited by applicant]
WO WO2018189517A1 · 2018 [cited by applicant]
WO WO2018197854A1 · 2018 [cited by applicant]
Brune et al. Sci Rep vol. 6, 19234, pp. 1-13 (Year: 2016). [cited by examiner]
Wussow et al., Human Cytomegalovirus Vaccine Based on the Envelope gH/gL Pentamer Complex. PLoS Pathog 10(11): e1004524). (Year: 2014). [cited by examiner]
Gordon et al., The Journal of Infectious Diseases, vol. 171, No. 6, pp. 1576-1585 (Year: 1995). [cited by examiner]
Chang et al., Cold Spring Harb Perspect Med Mar. 2015;5:a021493 (doi: 10.1101/cshperspect.a021493)). (Year: 2015). [cited by examiner]
Wussow et al., Vaccines , 5(4), 39 (Year: 2017). [cited by examiner]
Spaete et al., Virology vol. 193, pp. 853-861 (Year: 1993). [cited by examiner]
Altschul, S.F., “A protein alignment scoring system sensitive at all evolutionary distances,” [cited by applicant]
Altschul, S.F. et al., “Basic Local Alignment Search Tool,” [cited by applicant]
Arai, R. et al., “Design of the linkers which effectively separate domains of a bifunctional fusion protein,” [cited by applicant]
Brune, K.D. et al., “Plug-and-Display: decoration of Virus-Like Particles via isopeptide bonds for modular immunization,” [cited by applicant]
Brune, K.D. et al., “Dual Plug-and-Display Synthetic Assembly Using Orthogonal Reactive Proteins for Twin Antigen Immunization,” [cited by applicant]
Bruun, T.U.J. et al., “Engineering a Rugged Nanoscaffold To Enhance Plug-and-Display Vaccination,” [cited by applicant]
Chen, X. et al., “Fusion Protein Linkers: Property, Design and Functionality,” [cited by applicant]
Cheng, J. et al., “Cytomegalovirus Infection Causes an Increase of Arterial Blood Pressure,” [cited by applicant]
Devereux, J. et al., “A comprehensive set of sequence analysis programs for the VAX,” [cited by applicant]
Hofmann, I. et al., “Expression of the human cytomegalovirus pentamer complex for vaccine use in a CHO system,” [cited by applicant]
Joyce, M.G. et al., “Iterative structure-based improvement of a respiratory syncytial virus fusion glycoprotein vaccine,” [cited by applicant]
Karlin, S. et al., “Applications and statistics for multiple high-scoring segments in molecular sequences,” [cited by applicant]
Kaslow, D.C. et al., “RTS,S: Toward a first landmark on the Malaria Vaccine Technology Roadmap,” [cited by applicant]
Klein, J.S. et al., “Design and characterization of structured proteinlinkers with differing flexibilities,” [cited by applicant]
Krarup, A. et al., “A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism,” [cited by applicant]
Kushnir, N. et al., “Virus-like particles as a highly efficient vaccine platform: Diversity of targets and production systems and advances in clinical development,” [cited by applicant]
Leneghan, D.B. et al., “Nanoassembly routes stimulate conflicting antibody quantity and quality for transmission-blocking malaria vaccines,” [cited by applicant]
Li, L. et al., “Structural Analysis and Optimization of the Covalent Association between SpyCatcher and a Peptide Tag,” [cited by applicant]
Michel, M. et al., “Optimisation of secretion of recombinant HBsAg virus-like particles: Impact on the development of HIV-1/HBV bivalent vaccines,” [cited by applicant]
Thrane, S. et al., “Bacterial superglue enables easy development of efficient virus-like particle based vaccines,” [cited by applicant]
Valenzuela, P. et al., “Nucleotide sequence of the gene coding for the major protein of hepatitis B virus surface antigen,” [cited by applicant]
Veggiani, G. et al., “Superglue from Bacteria: Unbreakable Bridges for Protein Nanotechnology,” [cited by applicant]
Wang, X. et al., “RT-qPCR-based microneutralization assay for human cytomegalovirus using fibroblasts and epithelial cells,” [cited by applicant]
Wussow, F. et al., “Human Cytomegalovirus Vaccine Based on the Envelope gH/gL Pentamer Complex,” [cited by applicant]
Zakeri, B. et al., “Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesion,” [cited by applicant]
Search Report in GB Application No. 1807378.3, dated Feb. 1, 2019 (5 pages). [cited by applicant]
Search Report in GB Application No. 1807376.7, dated Feb. 1, 2019 (5 pages). [cited by applicant]
International Search Report in International Application No. PCT/GB2019/051245, mailed Oct. 29, 2019 (8 pages). [cited by applicant]
Pumpens, P. et al., “Construction of Novel Vaccines on the Basis of Virus-Like Particles: Hepatitis B Virus Proteins as Vaccine Carriers,” Ch. 9, pp. 205-248 in [cited by applicant]
Pushko, P. et al., “Development of Virus-Like Particle Technology from Small Highly Symmetric to Large Complex Virus-Like Particle Structures,” [cited by applicant]
Rutgers, T. et al., “Hepatitis B Surface Antigen as Carrier Matrix for the Repetitive Epitope of the Circumsporozoite Protein of [cited by applicant]
Wikipedia, “SpyCatcher,” available at https://en.wikipedia.org/wiki/SpyCatcher, last accessed Dec. 21, 2022 (8 pages). [cited by applicant]
Moffat, J.M. et al, “Hepatitis B virus-like particles access major histocompatibility class I and II antigen presentation pathways in primary dendritic cells”, Vaccine, vol. 31, pp. 2310-2316 (Apr. 2013). [cited by applicant]
Falloon et al., “An Adjuvanted, Postfusion F Protein-Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults”, The Journal of Infectious Disease, 2017, vol. 216, Issue 11, pp. 1362-1370. [cited by applicant]
Graham et al., “Novel antigens for RSV vaccines”, Current Opinions in Immunology, 2015, vol. 35, pp. 30-38. [cited by applicant]
Graham, “Vaccine development for respiratory syncytial virus”, Current Opinions in Virology, 2017, vol. 23, pp. 107-112. [cited by applicant]
Lilleri et al., “Fetal human cytomegalovirus transmission correlates with delayed maternal antibodies to gH/gL/pUL128-130-131 complex during primary infection”, PLoS One, 2013, vol. 8, Issue 3, Article No. e59863, pp. 1… [cited by applicant]
Wen et al., “Human cytomegalovirus gH/gL/UL128/UL130/UL131A complex elicits potently neutralizing antibodies in mice”, Vaccine, 2014, vol. 32, Issue 30, pp. 3796-3804. [cited by applicant]
Kotiw et al., “Immunological Response to Parenteral Vaccination with Recombinant Hepatitis B Virus Surface Antigen Virus-Like Particles Expressing Helicobacter pylori KatA Epitopes in a Murine H. pylori Challenge Model”… [cited by applicant]